News Releases

Date Title and Summary View
May 18, 2018
May 16, 2018
May 14, 2018
May 07, 2018
May 05, 2018
New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression
- Study in adults with treatment-resistant depression marks the first time an antidepressant has achieved superiority in a clinical trial for major depressive disorder that included a newly initiated oral antidepressant in both the control and placebo groups
- Study in elderly patients is the first large clinical trial in treatment-resistant depression in this population
- Results demonstrate the potential of esketamine nasal spray to address a significant unmet need for the more than 30 percent of people suffering from major depressive disorder who do not respond to two or more currently available antidepressants(1)
May 03, 2018
Johnson & Johnson to Participate in the 2018 UBS Global Health Care Conference
NEW BRUNSWICK, N.J. , May 3, 2018 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) will participate in the 2018 UBS Global Health Care Conference on Monday, May 21 st , at the Grand Hyatt , New York .   Sandi Peterson, Executive Vice President, Group Worldwide Chairman will represent the Company in a
May 02, 2018
Johnson & Johnson to Host Consumer and Medical Devices Business Review
NEW BRUNSWICK, N.J. , May 2, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Consumer and Medical Devices businesses for the investment community beginning with a continental breakfast and access to exhibits at 8:00 a.m. (Eastern Time) on Wednesday, May 16, 2018 at the
Apr 30, 2018
Apr 26, 2018
Johnson & Johnson Announces Dividend Increase of 7.1%
Johnson & Johnson Announces Dividend Increase of 7.1% NEW BRUNSWICK, N.J., April 26, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.84 per share to $0.90 per share.  The increase was
Apr 24, 2018
Johnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference
NEW BRUNSWICK, N.J. , April 24, 2018 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Deutsche Bank 43 rd Annual Health Care Conference on Wednesday, May 9 th , at The InterContinental Boston .  Mathai Mammen, MD, Ph.D., Global Head, Research & Development, Janssen
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.